Dayvigo Appetite & Cravings Changes: What the Evidence Actually Shows

Why Orexin Biology Makes This Question Worth Asking

Lemborexant blocks both orexin receptor subtypes, OX1R and OX2R, to suppress wake-promoting signals at night. That mechanism is straightforward for sleep. Less straightforward is the fact that the same orexin peptides (orexin-A and orexin-B, also called hypocretin-1 and hypocretin-2) are co-expressed in lateral hypothalamic neurons that govern feeding behavior, reward-seeking, and energy homeostasis. Animal studies published in Neuropharmacology showed that intracerebroventricular orexin-A injection increased food intake in rodents within 1 hour of administration, a finding that placed orexin firmly on the appetite-research map more than two decades ago.

Patients started asking whether blocking those same signals pharmaceutically could suppress appetite. It is a biologically reasonable question.

The Lateral Hypothalamus Connection

The lateral hypothalamus has been called a "feeding center" in classical neuroscience texts, and orexin neurons in that region project to the nucleus accumbens, ventral tegmental area, and other reward-circuit nodes. Research in the Journal of Neuroscience demonstrated that OX1R signaling modulates dopaminergic reward pathways that drive hedonic eating, eating motivated by palatability rather than caloric need. Blocking OX1R specifically may reduce cue-triggered food-seeking, at least in preclinical models.

OX2R, by contrast, is more tightly linked to sleep-wake switching via the tuberomammillary nucleus and locus coeruleus. Lemborexant blocks both subtypes with roughly equipotent affinity (Ki approximately 1.3 nM at OX1R and 1.6 nM at OX2R based on radioligand binding data cited in the FDA pharmacology review).

What Preclinical Models Suggest

Rodent studies using selective OX1R antagonists like SB-334867 have consistently reduced sucrose self-administration and high-fat food intake without proportionally reducing standard chow consumption. This pattern suggests that OX1R blockade might blunt reward-driven eating more than homeostatic eating. One paper in Psychopharmacology (Berlin) reported a 30 to 40% reduction in sucrose-seeking behavior in rats given SB-334867, effects that did not generalize to water intake. These are rodent data, not human data, but they inform the mechanistic hypothesis that a dual DORA like lemborexant could theoretically dampen hedonic cravings in humans.

The gap between rodent pharmacology and human clinical outcomes is wide, and clinicians should not treat preclinical signals as clinical predictions.

SUNRISE-1 and SUNRISE-2: What the Trials Actually Measured

SUNRISE-1 was a Phase 3, randomized, double-blind, placebo- and active-controlled trial published in JAMA Network Open in 2019 (N=291). Participants received lemborexant 5 mg, lemborexant 10 mg, zolpidem tartrate extended-release 6.25 mg, or placebo for 30 nights. The primary endpoint was subjective sleep onset latency on nights 1 and 2. SUNRISE-1 (PMID 31886325) found that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep assessed by polysomnography, with lemborexant 10 mg showing a mean latency of 12.8 minutes versus 27.3 minutes for placebo on night 1.

Appetite, food intake, body weight, and cravings were not primary or secondary endpoints in SUNRISE-1. No weight data were reported in the primary publication.

SUNRISE-2 Extension Data

SUNRISE-2 enrolled 949 participants and ran for 12 months, substantially longer than most insomnia drug trials. The SUNRISE-2 results published in Sleep confirmed durable efficacy on subjective total sleep time and sleep onset latency through month 12. Again, body weight and appetite were not pre-specified endpoints. The safety table in SUNRISE-2 lists the most common adverse events as somnolence (10.3% with lemborexant 10 mg vs. 1.2% placebo), headache, and nasopharyngitis. No appetite increase or decrease appears in the adverse-event table at a frequency exceeding 2%.

Reading the Absence of a Signal

The absence of an appetite signal in SUNRISE-1 and SUNRISE-2 does not prove lemborexant has no effect on eating behavior. Both trials were powered for sleep endpoints and were not designed to detect modest changes in caloric intake or food preference. Participants were not instructed to track diet, and no validated appetite or craving instruments (such as the Food Craving Inventory or Yale Food Addiction Scale) were administered. The negative finding is informative, but it is a null result in an underpowered domain, not a definitive exoneration.

Orexin, Sleep Debt, and the Real Driver of Post-Dose Cravings

Here is a clinically important point that gets missed in most drug-information summaries: improved sleep itself changes appetite. Chronic sleep deprivation raises ghrelin, lowers leptin, and increases preference for energy-dense foods. A landmark study in PLOS Medicine (Taheri et al., 2004, N=1,024) showed that short sleep duration (less than 8 hours) was associated with higher BMI and higher circulating ghrelin in a dose-dependent fashion. If lemborexant successfully treats insomnia and a patient begins sleeping 7 to 8 hours instead of 4 to 5, their ghrelin/leptin balance should improve over weeks.

Some patients report feeling less hungry after starting an orexin receptor antagonist. Sleep restoration, not direct orexin blockade, is the most plausible explanation for that subjective improvement.

The Opposite Pattern: Late-Night Eating

A different subset of patients reports increased appetite or late-night food-seeking after taking lemborexant. This is more likely a behavioral phenomenon than a pharmacological one. The 17-to-19-hour half-life means some sedation persists into the following day, and sedated states are associated with reduced dietary restraint and more impulsive food choices in laboratory paradigms. A 2012 study in Appetite found that experimentally induced sleepiness increased hedonic food intake by approximately 22% in healthy adults without altering hunger ratings on a visual analog scale, suggesting the mechanism is cognitive disinhibition rather than a true increase in homeostatic hunger.

Patients who take lemborexant and notice they are snacking more the following day should be asked about daytime sedation specifically. The snacking may trace back to the same residual somnolence rather than any direct orexigenic effect of the drug.

Sleep Architecture Changes and Metabolic Implications

Lemborexant preserves and may enhance slow-wave sleep (SWS) and REM sleep relative to zolpidem, based on polysomnographic data in SUNRISE-1. SWS is the sleep stage most tightly linked to growth hormone secretion and insulin sensitivity. Research in Diabetes Care (2010) demonstrated that selective SWS suppression over three nights reduced insulin sensitivity by 25% in healthy young adults. If lemborexant increases SWS duration compared to a benzodiazepine or z-drug, downstream metabolic effects on insulin and glucose regulation could differ, though this remains speculative without direct metabolic outcome data from lemborexant-specific trials.

Comparison With Other Orexin Antagonists

Suvorexant (Belsomra)

Suvorexant is the other FDA-approved dual orexin receptor antagonist, approved in 2014 at doses of 10 to 20 mg. Its receptor binding kinetics differ somewhat from lemborexant: suvorexant has a longer dissociation half-life from OX2R, which some pharmacologists argue contributes to its higher next-morning impairment rate. The suvorexant prescribing information similarly lists no appetite or weight changes as clinically significant adverse events. No head-to-head metabolic comparison between lemborexant and suvorexant exists in the published literature as of this writing.

Seltorexant (Pending Approval)

Seltorexant is a selective OX2R antagonist in late-stage development for insomnia and major depressive disorder. Because it spares OX1R, it may provide a pharmacological tool for isolating OX2R-specific sleep effects from OX1R-mediated appetite and reward effects. If seltorexant reaches approval, comparative metabolic data between seltorexant (OX2R-selective) and lemborexant (dual) would be scientifically useful for answering the appetite question more definitively.

What Clinicians Should Tell Patients Who Ask About Appetite

Patients will ask. The question usually comes in one of three forms:

1. "Will Dayvigo help me lose weight?"
2. "I started Dayvigo and I'm craving sweets at night, is that the drug?"
3. "I feel less hungry since starting Dayvigo, should I be worried?"

For question 1: No published randomized controlled trial supports lemborexant as a weight-management agent. The orexin biology is interesting but not yet translatable to a clinical recommendation. Patients seeking appetite suppression should be directed toward FDA-approved options, GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy, approved June 2021) or tirzepatide 15 mg (Zepbound, approved November 2023), where the evidence base is substantially stronger. STEP-1 (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo, a magnitude of effect that orexin antagonism has never approached in human trials.

For question 2: Late-night cravings after taking lemborexant are more likely explained by disinhibited eating under mild sedation than by any direct pharmacological orexin stimulation. The drug blocks orexin; it does not activate it. Review the patient's timing of dose administration, alcohol use (which potentiates sedation and lowers dietary restraint), and whether the cravings occur before peak sedation or after partial arousal.

For question 3: Reduced appetite is a plausible secondary consequence of improved sleep quality through the ghrelin/leptin axis, not a direct drug effect. Unless the appetite reduction is severe enough to cause clinically significant weight loss (defined by the FDA as 5% or more from baseline), no dose adjustment is warranted. If unexplained weight loss occurs, rule out other causes before attributing it to lemborexant.

Drug Interactions That Could Modify the Appetite Picture

CYP3A4 inhibitors increase lemborexant plasma exposure substantially. The prescribing information contraindicates concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) and recommends a dose reduction to 5 mg with moderate inhibitors (e.g., fluconazole, erythromycin). The FDA label for lemborexant notes that fluconazole (a moderate CYP3A4 inhibitor) increased lemborexant AUC by approximately 4-fold.

Higher plasma exposures mean more sustained and deeper orexin blockade. If appetite or craving changes are theoretically tied to OX1R blockade, they would be expected to be more pronounced in patients on CYP3A4 inhibitors, an untested but mechanistically coherent hypothesis. Clinicians managing patients on both fluconazole and lemborexant should document any appetite complaints and consider whether the interaction is contributing.

Special Populations

Patients With Obesity

Patients with obesity have altered orexin signaling at baseline. A study in Obesity Reviews found that cerebrospinal fluid orexin-A levels were lower in obese individuals compared to lean controls, suggesting that the orexin system may already be partially dysregulated by adiposity. Whether this alters the pharmacodynamic response to exogenous OX1R/OX2R blockade is unknown. Lemborexant has not been studied in trials specifically enrolling patients with BMI above 40 kg/m2 as a co-primary population.

Patients With Type 2 Diabetes

Improved sleep quality from any cause tends to improve glycemic metrics. The American Diabetes Association Standards of Medical Care in Diabetes acknowledge sleep disturbance as a contributor to insulin resistance, stating that "assessment of sleep patterns and disorders should be considered part of diabetes management." ADA Standards of Care, 2024. If lemborexant improves sleep duration and continuity in a patient with type 2 diabetes, modest improvements in fasting glucose or insulin sensitivity are biologically plausible, though lemborexant is not a diabetes drug and this effect has not been measured in a pre-specified metabolic endpoint trial.

Monitoring Recommendations for Clinicians Prescribing Lemborexant

Standard prescribing practice does not require appetite or weight monitoring for lemborexant. The following guidance is based on the intersection of orexin biology, the sleep-metabolism literature, and clinical practicality:

• Document baseline body weight at initiation, particularly in patients with obesity or type 2 diabetes, to provide a reference point if the patient later reports weight changes.
• Screen for residual next-morning sedation at the 2-week follow-up visit. Daytime sedation is the most likely behavioral pathway to disinhibited eating.
• In patients who report new or worsened nighttime eating after starting lemborexant, consider a formal screen for sleep-related eating disorder (SRED) or night eating syndrome (NES), both of which can coexist with insomnia. A 2018 review in Current Psychiatry Reports noted that SRED has been reported with sedative-hypnotics, including zolpidem, though the association with DORAs is not established.
• Patients who note reduced appetite and feel well do not require intervention. Reassure and continue to monitor.

The Current Evidence Gap and What Would Close It

The honest clinical answer is that no trial has been designed to answer the question of whether lemborexant meaningfully changes appetite or body weight in humans. Closing that gap would require a randomized, placebo-controlled trial in adults with insomnia that uses:

• Validated appetite instruments administered daily (e.g., the Visual Analog Scale for appetite or the Dutch Eating Behaviour Questionnaire)
• Continuous glucose monitoring or mixed-meal tolerance testing to capture metabolic endpoints
• Actigraphy-confirmed sleep duration to separate sleep-restoration effects from direct drug effects
• A minimum 12-week duration to allow the sleep-restoration metabolic effects to manifest

Until that trial exists, clinicians should counsel patients that the orexin system is involved in feeding behavior, that lemborexant targets that system, and that no reliable clinical evidence shows a meaningful appetite or weight effect at approved doses of 5 mg or 10 mg.